Serous retinal detachment following combined photodynamic therapy and intravitreal bevacizumab injection.
We report a case of serous retinal detachment following combined photodynamic therapy (PDT) and intravitreal bevacizumab injection in subfoveal choroidal neovascularization (CNV). A 53-year-old woman was diagnosed with subfoveal CNV secondary to age-related macular degeneration (AMD) and treated with combined PDT and intravitreal bevacizumab injection. One day after treatment, the patient experienced a sudden decline of vision and optical coherence tomography (OCT) showed serous retinal detachment involving the macula. She was managed conservatively with an oral steroid beginning on the second day of the combined treatment and the subretinal fluid started to decrease one week following the initiation of steroids. This case suggests that combined PDT and intravitreal injection of bevacizumab can be associated with serous retinal detachment. Additional studies are needed to establish the safety and complications following this treatment regimen.
Kim
Eui Yon
EY
Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea.
Kim
Jong Wan
JW
Kim
Jun Bum
JB
Lew
Ho Min
HM
D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007267:Injections; D008875:Middle Aged; D010778:Photochemotherapy / Q000009:adverse effects*; D012163:Retinal Detachment / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D014221:Triamcinolone / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D014221:Triamcinolone; D000068258:Bevacizumab